pemigatinib   Click here for help

GtoPdb Ligand ID: 9767

Synonyms: example 126 [WO2014007951] | INCB 54828 | INCB-54828 | INCB054828 | INCB54828 | Pemazyre®
Approved drug
pemigatinib is an approved drug (FDA (2020))
Compound class: Synthetic organic
Comment: Pemigatinib (INCB54828) is a FGFR inhibitor claimed in Incyte Corporation's patent WO2014007951 [3]. It is equipotent at FGFR subtypes 1-3 [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 83.16
Molecular weight 487.2
XLogP 2.02
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCN1C(=O)N(Cc2c1c1cc([nH]c1nc2)CN1CCOCC1)c1c(F)c(OC)cc(c1F)OC
Isomeric SMILES CCN1C(=O)N(Cc2c1c1cc([nH]c1nc2)CN1CCOCC1)c1c(F)c(OC)cc(c1F)OC
InChI InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)
InChI Key HCDMJFOHIXMBOV-UHFFFAOYSA-N
References
1. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG et al.. (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol, 21 (5): 671-684. [PMID:32203698]
2. Romero D. (2020)
Benefit from pemigatinib in cholangiocarcinoma.
Nat Rev Clin Oncol, 17 (6): 337. [PMID:32300194]
3. Wu L, Zhang C, He C, Sun Y, Lu L, Qian D-Q, Xu M, Zhou J, Yao W. (2014)
Substituted tricyclic compounds as FGFR inhibitors.
Patent number: WO2014007951. Assignee: Incyte Corporation. Priority date: 13/06/2012. Publication date: 09/01/2014.
4. (2020)
Pemigatinib Is Active in Some FGFR2-Altered Cholangiocarcinomas.
Cancer Discov, 10 (5): 639. [PMID:32245820]